A leading clinical stage biotechnology firm Cavion, Inc. has reportedly announced that outcomes from its Phase 2 clinical trial for CX-8998, its lead compound for essential tremor, will be showcased at a platform presentation during the American Academy of Neurology’s 71st Annual Meeting. According to sources familiar with the development, Cavion is designing oral small molecules created to selectively control the central nervous system’s T-type calcium channel activity, acting as a biological pacemaker to reinstate the brain’s natural paces. CX-8998, which is the company’s lead candidate is a first-grade T-type calcium channel modulator as well as the most progressive late-stage small molecule presently being developed for essential tremor. The candidates were assessed under the T-CALM Study, a Phase 2, placebo-controlled, double-blind, clinical trial conducted on 95 patients suffering from essential tremor based at 25 locations throughout the United States. Patients were randomly assigned one of the two treatment arms, getting either CX-8998 or a placebo. Around 64% of the subjects consumed the study drug in addition to some standard of care anti-tremor medications. Margaret Lee, Senior VP of Preclinical and Translational Sciences at Cavion, said in a statement that she is thrilled to present the outcomes of the company’s proof-of-concept Phase 2 T-CALM trial for CX-8998 for patients with essential tremor at the yearly Academy meeting. Lee further stated that the company looks forward to discussing its clinical path ahead as it works to address the unfulfilled need in this debilitating disease that can badly hamper people’s quality of life and has not attained any permitted medication in over three decades. For the record, Cavion is a privately owned clinical-stage biotechnology firm dedicated to developing treatments for patients with chronic and rare neurological diseases. The firm’s range of T-type calcium channel modulators are being developed to reinstate the brain’s natural rhythms in several neurological diseases like essential tremor, neuropathic pain, Parkinson’s disease tremor, and epilepsy with absence seizures, reported sources. Source Credits: https://www.businesswire.com/news/home/20190424005265/en/Cavion-Present-Results-Phase-2-Essential-Tremor